Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Diatide

This article was originally published in The Gray Sheet

Executive Summary

Diatide: Medical imaging agent manufacturer completes enrollment of 269 patients in a Phase III pivotal trial of its P829 injectable imaging product for detection and localization of lung cancer, the firm reports Dec. 29. Diatide plans to submit in the second quarter a new drug application for P829, which is comprised of a small-molecule, synthetic peptide and a molecule of technetium-99m. A conventional gamma camera is used to detect the technetium-99m molecule after the peptide in the agent binds to the somatostatin receptor, which is a growth hormone present in some cancers, the firm explains. Nycomed licenses and distributes P829 in Europe, South Africa and certain countries in the Middle East...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel